New Jersey Tightens Rules for ADHD Medications, Requiring In-Person Doctor Visits for Adults
As the state shifts away from pandemic-era flexibility, adults in New Jersey who depend on drugs like Adderall and Ritalin to treat ADHD may soon face new difficulties. A policy shift is set to take effect that will require many patients to visit their doctors in person more frequently, ending a system that allowed prescriptions to be issued through virtual appointments.
During the COVID-19 pandemic, emergency measures introduced by state leadership made it easier for patients to access controlled medications without physically visiting a healthcare provider. These short-term modifications made it possible for physicians to use telehealth consultations to prescribe popular stimulants for attention issues. During a public health emergency, the objective was to minimize in-person interactions while maintaining treatment access.
But those loosened regulations have since been reversed. Under the updated policy, adult patients must begin attending in-person appointments to continue receiving prescriptions for certain medications classified as Schedule II drugs. This group contains several potent painkillers as well as commonly used ADHD drugs like Adderall, Ritalin, and Vyvanse.
All adult patients in New Jersey must see their prescribing physician in person at least once every three months starting on May 16. Without these in-person visits, physicians will not be permitted to issue or renew prescriptions for these medications. The change applies to both new and existing patients, although those already receiving prescriptions were given a temporary grace period to comply with the new requirements.
This change may seriously interfere with many patients’ routines. Over the past few years, telehealth became a convenient option, allowing individuals to manage their condition with short virtual check-ins rather than long travel times and waiting periods. Some patients, particularly those with hectic work schedules or restricted access to local healthcare providers, are now worried about how they will adapt.
The state’s persistent lack of mental health specialists exacerbates the problem. A recent report from a mental health advocacy organization found that New Jersey currently has only about half the number of psychiatrists needed to adequately serve its population. With more than 1.3 million residents living with mental health conditions, securing timely in-person appointments may become increasingly difficult.
Healthcare experts warn that the return to stricter rules could lead to delays in treatment. Patients who are unable to quickly book appointments might face interruptions in their medication schedules, which can affect their daily functioning, work performance, and overall well-being. Legal and healthcare professionals have also noted that after several years of relaxed guidelines, transitioning back to stricter oversight may feel burdensome for many individuals.
Children under the age of 18 will not be affected in the same way. Even before the pandemic, younger patients were allowed to receive prescriptions for ADHD medications through telehealth visits. That exception will remain in place, meaning minors can continue accessing care remotely without the new in-person requirement.
The updated rules in New Jersey are more restrictive than current federal guidelines, which still allow telehealth prescribing for certain controlled substances through the end of 2026. Those federal measures were extended to avoid disruptions in care, particularly for patients in underserved areas or those with mobility challenges. It remains uncertain whether federal authorities will extend these allowances further.
At the state level, there has been little immediate response from lawmakers regarding potential changes or exceptions for adult patients. No legislation has yet been introduced to create a similar telehealth option for adults as exists for minors. Some advocates are calling for temporary solutions to give policymakers time to address access concerns, but no official action has been announced.
Data from the New Jersey Prescription Monitoring Program shows that more than 828,000 stimulant prescriptions were written in 2025 alone. This illustrates the number of residents who may be impacted by the new regulations.
As the deadline approaches, many patients may not yet be aware of the change. With the healthcare system already under strain, the shift back to in-person visits could place added pressure on both patients and providers. For now, individuals who depend on these medications are being urged to plan ahead, schedule appointments early, and stay informed about the evolving rules.
Sources
New Jersey Attorney General’s Office
New Jersey Drug Control Unit
New Jersey Prescription Monitoring Program
Inseparable (Mental Health Advocacy Organization)
